Friday, September 4, 2015

Pharma-government deals involve McKesson and maybe Teva

Teva Pharmaceuticals might build another facility in New Jersey and and McKesson was awarded a $31 billion contract to distribute pharmaceuticals to the Veterans Administration.

Pharma-government deals involve McKesson and maybe Teva

0 comments

Like some folks on Wall Street, some in the pharmaceutical community bemoan the existence of government.....until the government gives them money.

Two examples came Wednesday, when news emerged that Teva Pharmaceuticals might build another facility in New Jersey and and McKesson Inc. was awarded a $31 billion contract to distribute pharmaceuticals to the Veterans Administration.

Inquirer colleague Matt Katz, whose coverage of New Jersey Gov. Christie is first rate, shared a bit of pharma knowledge Wednesday as the governor mentioned that Teva Pharmaceuticals might open a facility in Florham Park.

Teva is based in Israel and company officials signed a "letter of cooperation" with Christie during his recent visit to that country. Recent New Jersey governors have made such trips.

Teva has facilities in Elmwood Park, Fairfield, Fairlawn, and Woodcliff Lakes. The state's Economic Development Authority said Teva would be eligible for $15 million in tax credits if it builds a research and development facility in Florham Park and creates 215 jobs.

Meanwhile, the Wall Street Journal and Bloomberg reported that McKesson was able to keep the contract with the VA, which could run over eight years. McKesson is the largest distributor in the United States. AmerisourceBergen, based in Valley Forge, and Cardinal Health are the other two big distributors had hoped to win the VA deal.

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell
Also on Philly.com:
letter icon Newsletter